An experimental drug cleared protein buildup in the brains of people with mild Alzheimer’s disease and slowed their mental decline, the results of a preliminary trial showed on Wednesday.
The outcome raised hopes that a treatment might finally be within reach for the memory and independence-robbing disease, but experts cautioned against overplaying the findings.
The drug, aducanumab, is only the latest antibody to show promise in an early, phase I drug trial, they said. Others ended up disappointing in the decisive phase III efficacy test.
“Although potentially this is an exciting story, it is important to temper any excitement with considerable caution,” said Robert Howard, a professor of old age psychiatry at University College London.
“It would be premature to conclude that this is likely to represent an effective treatment for Alzheimer’s disease,” Howard added.
Researchers in the US and Switzerland tested aducanumab, developed by biotech firm Biogen, on 165 people with early-stage Alzheimer’s disease for a period of one year.
Some were given a monthly injection of the antibody and others a placebo or dummy drug.
In the brains of those given the treatment, there was an “almost complete clearance” of so-called amyloid plaques, the researchers reported.
Amyloids are sticky proteins that clump together in deposits — one of the mechanisms suspected of causing Alzheimer’s.
“The effect of the antibody is very impressive,” said Roger Nitsch, a professor at the University of Zurich’s Institute for Regenerative Medicine, who coauthored the study.
After one year of treatment, “practically no beta-amyloid plaques could be detected in patients who received the highest dose,” a university statement said.
While the trial was not designed to test drug efficacy, the team did observe slower onset of symptoms in treated patients.
This supported the hypothesis that amyloid plaques are indeed what cause Alzheimer’s, the researchers said, but further tests are required to prove this once and for all.
“Indeed, confirmation that anti-AB [amyloid-beta] treatment slows cognitive decline would be a game-changer for how we understand, treat and prevent Alzheimer’s disease,” Eric Reiman of the Banner Alzheimer’s Institue in Phoenix, Arizona, said. “Now is the time to find out.”
However, the drug did have side effects, including fluid buildup on the brain and headaches.
Alzheimer’s disease is the most common form of dementia, which the WHO says affects nearly 50 million people worldwide — with about 7.7 million new cases diagnosed each year.
Old age is the major risk factor and there is no prevention or effective treatment for Alzheimer’s symptoms, which include memory loss and disorientation, as well as anxiety and aggressive behavior.
Like actor Gene Wilder, who passed away on Monday, people do not die of Alzheimer’s itself, but complications, which can include infections or malnutrition.
Last year, Eli Lilly said the drug solanezumab, also an antibody, showed promise when given to people in the early stages of Alzheimer’s.
Results from further testing of both drugs will be hotly anticipated in the months to come.
Outside experts expressed cautious optimism about the new study, published in the journal Nature.
“Let’s keep our fingers crossed for success in the next steps,” neuroscientist Richard Morris of the University of Edinburgh said.
Chinese President Xi Jinping (習近平) is to visit Russia next month for a summit of the BRICS bloc of developing economies, Chinese Minister of Foreign Affairs Wang Yi (王毅) said on Thursday, a move that comes as Moscow and Beijing seek to counter the West’s global influence. Xi’s visit to Russia would be his second since the Kremlin sent troops into Ukraine in February 2022. China claims to take a neutral position in the conflict, but it has backed the Kremlin’s contentions that Russia’s action was provoked by the West, and it continues to supply key components needed by Moscow for
Japan scrambled fighter jets after Russian aircraft flew around the archipelago for the first time in five years, Tokyo said yesterday. From Thursday morning to afternoon, the Russian Tu-142 aircraft flew from the sea between Japan and South Korea toward the southern Okinawa region, the Japanese Ministry of Defense said in a statement. They then traveled north over the Pacific Ocean and finished their journey off the northern island of Hokkaido, it added. The planes did not enter Japanese airspace, but flew over an area subject to a territorial dispute between Japan and Russia, a ministry official said. “In response, we mobilized Air Self-Defense
CRITICISM: ‘One has to choose the lesser of two evils,’ Pope Francis said, as he criticized Trump’s anti-immigrant policies and Harris’ pro-choice position Pope Francis on Friday accused both former US president Donald Trump and US Vice President Kamala Harris of being “against life” as he returned to Rome from a 12-day tour of the Asia-Pacific region. The 87-year-old pontiff’s comments on the US presidential hopefuls came as he defied health concerns to connect with believers from the jungle of Papua New Guinea to the skyscrapers of Singapore. It was Francis’ longest trip in duration and distance since becoming head of the world’s nearly 1.4 billion Roman Catholics more than 11 years ago. Despite the marathon visit, he held a long and spirited
The pitch is a classic: A young celebrity with no climbing experience spends a year in hard training and scales Mount Everest, succeeding against some — if not all — odds. French YouTuber Ines Benazzouz, known as Inoxtag, brought the story to life with a two-hour-plus documentary about his year preparing for the ultimate challenge. The film, titled Kaizen, proved a smash hit on its release last weekend. Young fans queued around the block to get into a preview screening in Paris, with Inoxtag’s management on Monday saying the film had smashed the box office record for a special cinema